Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ...United Arab Emirates

CNBC - Economy
Novo Nordisk defends disappointing next-gen obesity drug: It will be an important product
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' )

Apple Storegoogle play

Also on site :



Latest News